» Articles » PMID: 23160780

Lifestyle Factors, Autoimmune Disease and Family History in Prognosis of Non-hodgkin Lymphoma Overall and Subtypes

Overview
Journal Int J Cancer
Specialty Oncology
Date 2012 Nov 20
PMID 23160780
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Lifestyle factors and medical history are known to influence risk of non-Hodgkin lymphoma (NHL). Whether these factors affect the prognosis of NHL, especially its subtypes, is unclear. To investigate this, the association between these factors and all-cause and lymphoma-related mortality was assessed in a population-based cohort of 1,523 Swedish NHL patients included in the Scandinavian Lymphoma Etiology study in 1999-2002. Participants contributed time from NHL diagnosis until death or October 1, 2010, with virtually complete follow-up through linkage to the Swedish Cause of Death Register. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using stratified and multivariable-adjusted Cox regression models. During a median follow-up of 8.8 years, 670 patients (44%) died, with the majority of deaths attributed to lymphoma (86%). Current versus never smoking at diagnosis was associated with increased rate of all-cause death for all NHL (HR = 1.5, 1.2-1.8) and diffuse large B-cell lymphoma (HR = 1.8, 1.2-2.7). Low educational level (HR = 1.3, 1.1-1.7, <9 vs. >12 years) and NHL risk-associated autoimmune disease (HR = 1.4, 1.0-1.8) were associated with death for all NHL combined. However, evidence of an association with lymphoma-related death was limited. Body mass index, recent sunbathing and family history of hematopoietic malignancy were not consistently associated with death after NHL or its specific subtypes. These results add to the evidence that cigarette smoking, socioeconomic status and certain autoimmune diseases affect survival after NHL. Further investigations are needed to determine how these factors should be incorporated into clinical prognostic assessment.

Citing Articles

Autoimmune disease and risk of lymphoma: analysis from real-world data and Mendelian randomization study.

Zhan L, Chen S, Liu Y, Lu T, Yu Z, Wang X BMC Cancer. 2025; 25(1):351.

PMID: 40000981 PMC: 11863826. DOI: 10.1186/s12885-025-13754-4.


Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results From the Global Burden of Disease Study 2019.

Cai W, Zeng Q, Zhang X, Ruan W Front Med (Lausanne). 2021; 8:738693.

PMID: 34631756 PMC: 8494781. DOI: 10.3389/fmed.2021.738693.


Body mass index and survival of patients with lymphoma.

Chihara D, Larson M, Robinson D, Thompson C, Maurer M, Casulo C Leuk Lymphoma. 2021; 62(11):2671-2678.

PMID: 34121594 PMC: 8771423. DOI: 10.1080/10428194.2021.1929956.


A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA)....

Ghesquieres H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P BMC Public Health. 2021; 21(1):432.

PMID: 33653294 PMC: 7927409. DOI: 10.1186/s12889-021-10433-4.


The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review.

Taylor P, Atzeni F, Balsa A, Gossec L, Muller-Ladner U, Pope J J Clin Med. 2021; 10(3).

PMID: 33535498 PMC: 7867048. DOI: 10.3390/jcm10030509.